In the large subgroup of patients undergoing cancer surgery (69% of the patient population), the VTE rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group.
Suures vähioperatsiooni patsientide alamrühmas (69% patsientidest) oli VTE esinemissagedus 4, 7% fondapariinuksi grupis ja 7, 7% daltepariini grupis. on